Chargesheet filed against BJP MP Gautam Gambhir in cheating case

Srinagar, Jun 19: Suspended Jammu and Kashmir DSP Davinder Singh, arrested while ferrying two Hizb-ul-Mujahideen terrorists in a vehicle on the Srinagar-Jammu Highway earlier this year, was granted bail by a Delhi court on Friday, his lawyer said.

Singh and another accused in the case - Irfan Shafi Mir - were granted the relief by the court in a case filed by special cell of Delhi Police, noting that the probe agency failed to file charge sheet within 90 days from his arrest, as prescribed under law, their lawyer M S Khan said.

The bail was granted on a personal bond of Rs 1 lakh and two sureties of like amount.

Thiruvananthapuram, Mar 29: Kerala Chief Minister Pinarayi Vijayan on Saturday expressed his concern over the ''non-cooperation from the Karnataka Government in removing the roadblocks erected by them in the roads bordering Malapuram district''.

Addressing a press conference at the Government Secretariat, the Chief Minister said, "Karnataka has not heeded to our request to remove the roadblocks. I have been trying to contact their Chief Minister B S Yeddyurappa but not able to reach him."

"We have briefed the Union Minister D V Sadananda Gowda and he has offered to resolve the issue. Our Chief Secretary has also briefed the Central Cabinet Secretary and we expect a resolution soon," he added.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.